Org 9487, rapacuronium (Raplon) generated considerable excitement at the time of the phase III clinical trials in 1999.
Bronchospasm proved to be the biggest problem with rapacuronium.
Rapacuronium (Org 9487): do we have a replacement for succinylcholine?
Rapacuronium was supposed to rival succinylcholine with regards to onset and offset, yet was removed from the market shortly after its release related to reports of bronchospasm and even death in some patients.
Rapacuronium preferentially antagonizes the function of M2 versus M3 muscarinic receptors in guinea pig airway smooth muscle.
Rapacuronium and the risk of bronchospasm in pediatric patients.
Effects of rapacuronium on respiratory function during general anesthesia: a comparison with cisatracurium.
The pharmacokinetics of rapacuronium and its active metabolite, ORG 9488, were prospectively studied in 11 patients.
Rapacuronium is a short-duration, rapid-onset neuromuscular blocking agent that was gaining popularity as a replacement drug for succinylcholine when it was withdrawn by the manufacturing pharmaceutical company because of side effects related to bronchospasm.
Some patients with a severely diseased liver still clear rapacuronium at an apparently normal rate (6, 7).
In phase 1, mixed-effects population models were fitted to the rapacuronium plasma concentration data from all 3 stages of the operation.
The values for the pharmacokinetics of rapacuronium were fixed to the values determined in the analyses described above (i.